Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 255

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 255
---
      $                   32,533  
  Consulting fees                                 422,522                       410,066                         453,519  
  Share based compensation                        185,843                       124,808                         772,786  
                                 $                608,365      $                534,874      $                1,258,838  
  Directors:                                                                                                             
  Directors’ fees and            $                242,603      $                182,261      $                  124,746  
  Share based compensation                        296,728                       121,981                          43,485  
                                 $                539,331      $                304,242      $                  168,231  

  (ii)      Balances with related parties  

                         October 31,                  October 31,              
                         2024                         2023                     
 ───────────────────────────────────────────────────────────────────────────────
  Amounts owed           $                29,498      $                29,666  
  Amounts                                 19,464                       12,767  
                         $                48,962      $                42,433  

  On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“ SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain...  
                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        
  In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate it’s and SciSparc’s combination treatment for obesity and metabolic syndrome.         
                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        
  To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they will enter into a joint ventu...  
                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        
  The Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $ 50,319, $ 141,409 and $ 194,205 for the years ended October...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  The Company shares office space with SciSparc and participates  

F-21

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)